ERBB2 and breast cancer: In a subgroup analysis, we found that ctDNA alteration detection in patients with HR-positive, ERBB2-negative breast cancer was associated with reduced survival (hazard ratio, 1.38; 95% CI, 1.15-1.61; P < .001) (eFigure 2 in Supplement 1).